Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.
News|Videos|October 18, 2023
Why You Should Attend the 2023 Psychiatric Times World CME Conference
Author(s)John J. Miller, MD
Our Editor in Chief explains why you should attend our conference!
Advertisement
John J. Miller, MD, the Editor in Chief of Psychiatric Times, is excited for our virtual conference. Here's why you should be too!
You can register
Dr Miller is Medical Director, Brain Health, Exeter, New Hampshire; Editor in Chief, Psychiatric Times®; Staff Psychiatrist, Seacoast Mental Health Center, Exeter; Consulting Psychiatrist, Exeter Hospital, Exeter; Consulting Psychiatrist, Insight Meditation Society, Barre, Massachusetts.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Top 7 Atypical Psychedelics: A Brief Clinical Guide
2
Positive Topline Phase 3 Study Results: Lumateperone for Manic Episodes in Bipolar I Disorder
3
New Analyses of HLP003 for the Adjunctive Treatment of MDD
4
Positive Phase 1b Results Demonstrate Clinical Proof-of-Concept for ALKS 7290 in Adults With ADHD
5